The purpose of this study is to learn if aripiprazole is effective for the treatment of patients with acute symptoms of Bipolar disorder.

Condition	Treatment or Intervention	Phase
Bipolar Disorder	Drug: aripiprazole	Phase III

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

Patients with acute symptoms of Bipolar Disorder

Alabama
      Local Institution, Tuscaloosa,  Alabama,  United States
Arizona
      Local Institution, Little Rock,  Arizona,  United States
California
      Local Institution, Chula Vista,  California,  United States
      Local Institution, Beachwood,  California,  United States
      Local Institution, San Clemente,  California,  United States
      Local Institution, Stanford,  California,  United States
      Local Institution, San Diego,  California,  United States
      Local Institution, Riverside,  California,  United States
      Local Institution, San Diego,  California,  United States
District of Columbia
      Local Institution, Washington,  District of Columbia,  United States
Florida
      Local Institution, Winter Park,  Florida,  United States
      Local Institution, North Miami,  Florida,  United States
Hawaii
      Local Institution, Honolulu,  Hawaii,  United States
Illinois
      Local Institution, Chicago,  Illinois,  United States
Indiana
      Local Institution, Indianapolis,  Indiana,  United States
Kentucky
      Local Institution, Louisville,  Kentucky,  United States
Massachusetts
      Local Institution, Belmont,  Massachusetts,  United States
      Local Institution, Newton Center,  Massachusetts,  United States
Michigan
      Local Institution, New Baltimore,  Michigan,  United States
New York
      Local Institution, Lawrence,  New York,  United States
North Carolina
      Local Institution, Butner,  North Carolina,  United States
Ohio
      Local Institution, Cincinnati,  Ohio,  United States
      Local Institution, Medina,  Ohio,  United States
      Local Institution, Cincinnati,  Ohio,  United States
Pennsylvania
      Local Institution, Philadelphia,  Pennsylvania,  United States
Texas
      Local Institution, Austin,  Texas,  United States
      Local Institution, Houston,  Texas,  United States
      Local Institution, Houston,  Texas,  United States
Virginia
      Local Institution, Falls Church,  Virginia,  United States
Washington
      Local Institution, Bellevue,  Washington,  United States

Study ID Numbers:  CN138-074
Record last reviewed:  February 2004
Last Updated:  October 13, 2004
Record first received:  May 7, 2002
ClinicalTrials.gov Identifier:  NCT00036101
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08